<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04869956</url>
  </required_header>
  <id_info>
    <org_study_id>2021-2-7-HCUVA</org_study_id>
    <nct_id>NCT04869956</nct_id>
  </id_info>
  <brief_title>Gut Microbiome Modification Through Dietary Intervention in Patients With Colorectal Cancer: Response to Surgery</brief_title>
  <official_title>Gut Microbiome Modification Through Dietary Intervention in Patients With Colorectal Cancer: Response to Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will conduct an open, controlled, randomized clinical trial, in patients&#xD;
      with scheduled surgical intervention for CRC in the General Surgery and Digestive System Unit&#xD;
      of the Virgen de la Arrixaca University Hospital (Murcia, Spain). All the included&#xD;
      individuals must have passed the protocol of the Virgen de la Arrixaca University Hospital to&#xD;
      be candidates for elective major surgery for CRC and must sign the informed consent after&#xD;
      being informed of the objectives and the methodology of the study. The Helsinki Declaration&#xD;
      will be followed during the duration of the project.&#xD;
&#xD;
      Patients will be randomized in a 1:1 ratio after receiving a diagnosis of CRC in the&#xD;
      endoscopic evaluation; in the control arm, patients will receive standard nutritional&#xD;
      recommendations, while patients in the intervention arm will be advised to follow a&#xD;
      high-fiber diet rich in PUFAs (total dietary intake of at least 30 grams of fiber per day,&#xD;
      and of at least 3 grams of PUFAs per day from food, not supplements) at least 4 weeks before&#xD;
      surgery&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 31, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>open, controlled, randomized clinical trial</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of anastomotic leakage</measure>
    <time_frame>360 Days from Baseline</time_frame>
    <description>Number of anastomotic leakage</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Surgical site infection</measure>
    <time_frame>360 Days from Baseline</time_frame>
    <description>Number of site infection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in gut microbiome composition</measure>
    <time_frame>360 Days from Baseline</time_frame>
    <description>changes in gut microbiota composition by 16S rRNA gene sequencing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum levels of inflammation markers</measure>
    <time_frame>360 Days from Baseline</time_frame>
    <description>Blood samples will be used to determine markers of inflammation (IL-6, IL-1β, IL-10 and TNFα), and markers of intestinal permeability (zonulin)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospitalization after surgery</measure>
    <time_frame>360 Days from Baseline</time_frame>
    <description>Number of days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrences of CRC after surgery</measure>
    <time_frame>360 Days from Baseline</time_frame>
    <description>Number of recurrences</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patients will receive standard nutritional recommendations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intervencion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high-fiber diet rich in PUFAs (total dietary intake of at least 30 grams of fiber per day, and of at least 3 grams of PUFAs per day from food, not supplements) at least 4 weeks before surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Intervencion</intervention_name>
    <description>high-fiber diet rich in PUFAs (total dietary intake of at least 30 grams of fiber per day, and of at least 3 grams of PUFAs per day from food, not supplements) at least 4 weeks before surgery</description>
    <arm_group_label>intervencion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>standard</intervention_name>
    <description>standard nutritional recommendations</description>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 18-80 years old.&#xD;
&#xD;
          -  After clinical diagnosis of CRC (stage I-III), the doctor has recommended and arranged&#xD;
             for CRC surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of stage IV CRC.&#xD;
&#xD;
          -  Current gastrointestinal illness other than gastroesophageal reflux disease or&#xD;
             hemorrhoids (such as celiac disease, inflammatory bowel disease, malabsorptive&#xD;
             bariatric procedures, etc.).&#xD;
&#xD;
          -  Chronic liver or kidney disease.&#xD;
&#xD;
          -  History of cardiac disease.&#xD;
&#xD;
          -  Positive genetic test for inherited polyposis syndromes (such as familial adenomatous&#xD;
             polyps, hereditary non-polyposis colon cancer syndromes, etc).&#xD;
&#xD;
          -  Alcoholism or illicit drug use.&#xD;
&#xD;
          -  Antibiotic use within the past 2 months.&#xD;
&#xD;
          -  Dietary supplement use including pre- or probiotics within the past month.&#xD;
&#xD;
          -  History of intestinal cancer, inflammatory bowel disease, celiac disease, or&#xD;
             malabsorptive bariatric surgery.&#xD;
&#xD;
          -  Inflammatory or connective tissue disease (such as lupus, scleroderma, rheumatoid&#xD;
             arthritis, etc.).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bruno Ramos Molina</last_name>
    <phone>968369500</phone>
    <email>bruno.ramos@imib.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Biomedical Research Institute of Murcia (IMIB-Arrixaca)</name>
      <address>
        <city>Murcia</city>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Bruno Ramos Molina</last_name>
      <email>bruno.ramos@imib.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 28, 2021</study_first_submitted>
  <study_first_submitted_qc>April 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2021</study_first_posted>
  <last_update_submitted>May 3, 2021</last_update_submitted>
  <last_update_submitted_qc>May 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Microbiome</keyword>
  <keyword>Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

